Binding of serum albumin to the anthelmintic drugs albendazole, triclabendazole and their sulphoxides

Veterinary Parasitology

Volumn 171, Issue 1-2, 2010, Pages 172-175

  Chambers, Emma ^a   Hoey, Elizabeth M ^a   Trudgett, Alan ^a   Fairweather, Ian ^a   Timson, David J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

ABZ; Bovine serum albumin; Drug binding; Fasciola hepatica.; Liver fluke; TCBZ

Indexed keywords

ALBENDAZOLE; SERUM ALBUMIN; TRICLABENDAZOLE; TRYPTOPHAN;

ARTICLE; BINDING AFFINITY; DRUG PROTEIN BINDING; FASCIOLIASIS; FLUORESCENCE ANALYSIS; GEL ELECTROPHORESIS;

ALBENDAZOLE; ANIMALS; ANTHELMINTICS; BENZIMIDAZOLES; BINDING, COMPETITIVE; CATTLE; FASCIOLA HEPATICA; FASCIOLIASIS; MICROSCOPY, FLUORESCENCE; SERUM ALBUMIN; SULFOXIDES;

BOVINAE; FASCIOLA HEPATICA;

EID: 77953617590     PISSN: 03044017     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetpar.2010.02.043     Document Type: Article

References (42)

1. Alvarez L.I., Imperiale F.A., Sanchez S.F., Murno G.A., Lanusse C.E. Uptake of albendazole and albendazole sulphoxide by Haemonchus contortus and Fasciola hepatica in sheep. Vet. Parasitol. 2000, 94:75-89.
2. Alvarez-Bujidos M.L., Ortiz A.I., Negro A., Cubria J.C., Ordonez D. Pharmacokinetics of triclabendazole in rabbits. Comp. Biochem. Physiol. C 1993, 106:805-808.
3. Alvarez-Sanchez M.A., Mainar-Jaime R.C., Perez-Garcia J., Rojo-Vazquez F.A. Resistance of Fasciola hepatica to triclabendazole and albendazole in sheep in Spain. Vet. Rec. 2006, 159:424-425.
4. Bennett J.L., Kohler P. Fasciola hepatica: action in vitro of triclabendazole on immature and adult stages. Exp. Parasitol. 1987, 63:49-57.
5. Boray J.C. Diseases of Domestic Animals Caused by Flukes 1994, Food and Agricultural Organisation of the United Nations, Rome, 49 pp.
6. Brennan G.P., Fairweather I., Trudgett A., Hoey E., McCoy, McConville M., Meaney M., Robinson M., McFerran N., Ryan L., Lanusse C., Mottier L., Alvarez L., Solana H., Virkel G., Brophy P.M. Understanding triclabendazole resistance. Exp. Mol. Pathol. 2007, 82:104-109.
7. Buchanan J.F., Fairweather I., Brennan G.P., Trudgett A., Hoey E.M. Fasciola hepatica: surface and internal tegumental changes induced by treatment in vitro with the sulphoxide metabolite of albendazole ('Valbazen'). Parasitology 2003, 126:141-153.
8. de Silva N., Guyatt H., Bundy D. Anthelmintics. A comparative review of their clinical pharmacology. Drugs 1997, 53:769-788.
9. Delatour P., Benoit E., Lechenet J., Besse S. Pharmacokinetics in sheep and cattle of albendazole administered by an intraruminal slow release capsule. Res. Vet. Sci. 1990, 48:271-275.
10. Dominguez L., Fagiolino P., Gordon S., Manta E. Bioavailability comparison between albendazole and albendazole sulphoxide in rats and man. Farmaco 1995, 50:697-702.
11. Fairweather I. Triclabendazole: new skills to unravel an old(ish) enigma. J. Helminthol. 2005, 79:227-234.
12. Fetterer R.H. The effect of albendazole and triclabendazole on colchicine binding in the liver fluke Fasciola hepatica. J. Vet. Pharmacol. Ther. 1986, 9:49-54.
13. Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., Curry S. Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol. 2005, 353:38-52.
14. Hennessy D.R., Lacey E., Steel J.W., Prichard R.K. The kinetics of triclabendazole disposition in sheep. J. Vet. Pharmacol. Ther. 1987, 10:64-72.
15. Jung H., Medina L., Garcia L., Fuentes I., Moreno-Esparza R. Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J. Pharm. Pharmacol. 1998, 50:43-48.
16. Kenyon F., Sargison N.D., Skuce P.J., Jackson F. Sheep helminth parasitic disease in south eastern Scotland arising as a possible consequence of climate change. Vet. Parasitol. 2009, 163:293-297.
17. Kinabo L.D., Bogan J.A. Pharmacokinetics and efficacy of triclabendazole in goats with induced fascioliasis. J. Vet. Pharmacol. Ther. 1988, 11:254-259.
18. Kragh-Hansen U., Chuang V.T., Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol. Pharm. Bull. 2002, 25:695-704.
19. Lacey E., Prichard R.K. Interactions of benzimidazoles (BZ) with tubulin from BZ-sensitive and BZ-resistant isolates of Haemonchus contortus. Mol. Biochem. Parasitol. 1986, 19:171-181.
20. Lubega G.W., Prichard R.K. Interaction of benzimidazole anthelmintics with Haemonchus contortus tubulin: binding affinity and anthelmintic efficacy. Exp. Parasitol. 1991, 73:203-213.
21. MacDonald L.M., Armson A., Thompson A.R., Reynoldson J.A. Characterisation of benzimidazole binding with recombinant tubulin from Giardia duodenalis. Encephalitozoon intestinalis, and Cryptosporidium parvum. Mol. Biochem. Parasitol. 2004, 138:89-96.
22. Marquardt D. An algorithm for least squares estimation of nonlinear parameters. SIAM J. Appl. Math. 1963, 11:431-441.
23. Marriner S.E., Bogan J.A. Pharmacokinetics of albendazole in sheep. Am. J. Vet. Res. 1980, 41:1126-1129.
24. Mas-Coma S., Valero M.A., Bargues M.D. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Adv. Parasitol. 2009, 69:41-146.
25. Mas-Coma S., Valero M.A., Bargues M.D. Climate change effects on trematodiases, with emphasis on zoonotic fascioliasis and schistosomiasis. Vet. Parasitol. 2009, 163:264-280.
26. Mohammed Ali N.A., Bogan J.A., Marriner S.E., Richards R.J. Pharmacokinetics of triclabendazole alone or in combination with fenbendazole in sheep. J. Vet. Pharmacol. Ther. 1986, 9:442-445.
27. Moll L., Gaasenbeek C.P., Vellema P., Borgsteede F.H. Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in The Netherlands. Vet. Parasitol. 2000, 91:153-158.
28. Mottier L., Alvarez L., Ceballos L., Lanusse C. Drug transport mechanisms in helminth parasites: passive diffusion of benzimidazole anthelmintics. Exp. Parasitol. 2006, 113:49-57.
29. Oxberry M.E., Geary T.G., Winterrowd C.A., Prichard R.K. Individual expression of recombinant α- and β-tubulin from Haemonchus contortus: polymerization and drug effects. Protein Expr. Purif. 2001, 21:30-39.
30. Peters T., Anfinsen C.B. Net production of serum albumin by liver slices. J. Biol. Chem. 1950, 186:805-813.
31. Robinson M.W., Dalton J.P. Zoonotic helminth infections with particular emphasis on fasciolosis and other trematodiases. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2009, 364:2763-2776.
32. Robinson M.W., Trudgett A., Hoey E.M., Fairweather I. The effect of the microtubule inhibitor tubulozole-C on the tegument of triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol. Res. 2003, 91:117-129.
33. Robinson M.W., Trudgett A., Hoey E.M., Fairweather I. Triclabendazole-resistant Fasciola hepatica: β-tubulin and response to in vitro treatment with triclabendazole. Parasitology 2002, 124:325-338.
34. Ryan L.A., Hoey E., Trudgett A., Fairweather I., Fuchs M., Robinson M.W., Chambers E., Timson D.J., Ryan E., Feltwell T., Ivens A., Bentley G., Johnston D. Fasciola hepatica expresses multiple α- and β-tubulin isotypes. Mol. Biochem. Parasitol. 2008, 159:73-78.
35. Stitt A.W., Fairweather I. The effect of the sulphoxide metabolite of triclabendazole ('Fasinex') on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica. Parasitology 1994, 108:555-567.
36. Stitt A.W., Fairweather I. Fasciola hepatica: tegumental surface changes in adult and juvenile flukes following treatment in vitro with the sulphoxide metabolite of triclabendazole (Fasinex). Parasitol. Res. 1993, 79:529-536.
37. Sudlow G., Birkett D.J., Wade D.N. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 1975, 11:824-832.
38. Thomas I., Coles G.C., Duffus K. Triclabendazole-resistant Fasciola hepatica in southwest Wales. Vet. Rec. 2000, 146:200.
39. Toner E., McConvery F., Brennan G.P., Meaney M., Fairweather I. A scanning electron microscope study on the route of entry of triclabendazole into the liver fluke Fasciola hepatica. Parasitology 2009, 136:523-535.
40. Toutain P.L., Bousquet-Melou A. Free drug fraction vs free drug concentration: a matter of frequent confusion. J. Vet. Pharmacol. Ther. 2002, 25:460-463.
41. van den Enden E. Pharmacotherapy of helminth infection. Expert Opin. Pharmacother. 2009, 10:435-451.
42. Virkel G., Lifschitz A., Sallovitz J., Pis A., Lanusse C. Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep. J. Vet. Pharmacol. Ther. 2006, 29:213-223.